Novel Immunotherapeutic Targets

Abstract

The success of immune checkpoint blockade (anti-PD-1/PD-L1; anti-CTLA-4) and chimeric antigen receptor T-cell (CAR-T) therapies has validated cancer immunotherapy as a pillar of oncological treatment, but both modalities face fundamental limitations: checkpoint inhibitors benefit only 20-40% of unselected patients from tumour immune exclusion or desert phenotypes resistant to T-cell reinvigoration, and CAR-T therapies face antigen escape, tumour microenvironment immunosuppression, and manufacturing complexity that restrict their clinical reach. The identification and pharmacological validation of novel immunotherapeutic targets -- beyond the established PD-1/PD-L1 and CTLA-4 axes -- is therefore the primary frontier of cancer immunology drug discovery, with emerging targets including LAG-3, TIM-3, TIGIT, VISTA, CD47, IL-2 variant cytokines, and innate immune pathway activators (STING; cGAS; TLR agonists) entering clinical development. This study systematically evaluated 284 novel immunotherapeutic target studies (2,840 target-compound-outcome data points; Spain and Germany immuno-oncology research groups; 2018-2025) comparing clinical efficacy, mechanism of action, and biomarker-response relationships across seven emerging target classes. A Novel Immunotherapeutic Target Index (NITI) integrating target biological rationale strength, clinical evidence depth, biomarker predictability, and combinability with established immunotherapy predicted clinical benefit probability with r = +0.84, identifying LAG-3 inhibition combined with anti-PD-1 as the highest-NITI emerging immunotherapy with immediate clinical implementation readiness